Status:
COMPLETED
Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
Brief Summary
This study is to evaluate the safety and the effectiveness of treatment with tacrolimus and biological agents.
Detailed Description
The purpose of this study is to confirm the safety of 24 weeks-treatment with the combination of tacrolimus + biological agents, and to assess the efficacy using SDAI, CDAI, DAS28-CRP, MMP-3, MHAQ in ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- patients with rheumatoid arthritis who have been treated with biological agents over 8 weeks but have not achieved SDAI remission (SDAI \< 3.3)
Exclusion
Key Trial Info
Start Date :
August 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
664 Patients enrolled
Trial Details
Trial ID
NCT01870908
Start Date
August 1 2012
End Date
March 1 2015
Last Update
October 5 2015
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Chūbu, Japan
2
Hokkaido, Japan
3
Kansai, Japan
4
Kantou, Japan